Follow-up eligibility and predictive value estimation in hepatocellular carcinoma risk stratification
Digestive and Liver Disease · 2026-10
DOI: 10.1016/j.dld.2026.09.021 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2026-10. Verfasst von Liverinto-Panagiotis Mela. Beteiligte Einrichtung: Department of Internal Medicine, General Hospital of Chalkida, Vathrovouni Area, Chalkida, 34100, Greece. Electronic address: melapanagiotis@gmail.co…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
I read with interest the multicenter cohort study by Moussa et al. comparing the Toronto HCC Risk Index (THRI) with the aMAP score for identifying patients with cirrhosis at sufficiently low hepatocellular carcinoma (HCC) risk to potentially defer surveillance [1]. The large multicenter cohort, head-to-head comparison, and competing-risk sensitivity analysis are important strengths. Two methodological aspects may nevertheless warrant clarification before the reported low-risk performance is translated into surveillance decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, General Hospital of Chalkida, Vathrovouni Area, Chalkida, 34100, Greece. Electronic address: melapanagiotis@gmail.com.
Zitieren
APA
Mela, L. P. (2026). Follow-up eligibility and predictive value estimation in hepatocellular carcinoma risk stratification. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.09.021
Vancouver
Mela LP. Follow-up eligibility and predictive value estimation in hepatocellular carcinoma risk stratification. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.09.021
BibTeX
@article{Mela2026,
author = {Mela, Liverinto-Panagiotis},
title = {Follow-up eligibility and predictive value estimation in hepatocellular carcinoma risk stratification},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2026.09.021}
}
EUVIMED